KevinLoringWinthropMD
Infectious Disease • Portland, ORAssistant Professor, Ophthalmology, Oregon Health and Science University School of Medicine
Are you Dr. Winthrop?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 47 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3375 SW Terwilliger Blvd
Portland, OR 97239Phone+1 503-494-7890Fax+1 503-494-0470
Summary
- Dr. Kevin Winthrop, MD is an infectious disease specialist in Portland, Oregon. He is currently licensed to practice medicine in Oregon, Washington, and Florida. He is affiliated with Portland HCS and OHSU Hospital.
Education & Training
Legacy Health/Emanuel Medical CenterResidency, Internal Medicine, 2004 - 2006- California Department of Public HealthFellowship, Maxillofacial Pathology, 2002 - 2002
Oregon Health and Science University School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 1999 - Present
WA State Medical License 2024 - 2026
OR State Medical License 2004 - 2025
FL State Medical License 2018 - 2020- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria Start of enrollment: 2012 Apr 19
- A PILOT STUDY OF THE SAFETY AND EFFECTIVENESS OF THE LIVE ZOSTER VACCINE IN ANTI-TNF USERS Start of enrollment: 2014 May 01
- Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) Start of enrollment: 2016 May 01
- Join now to see all
Publications & Presentations
PubMed
- 50 citationsTreatment of Mycobacterium abscessus ComplexLuke Strnad, Kevin L. Winthrop
Seminars in Respiratory and Critical Care Medicine. 2018-06-01 - 94 citationsOral surveillance and JAK inhibitor safety: the theory of relativity.Kevin L Winthrop, Stanley B Cohen
Nature Reviews. Rheumatology. 2022-05-01 - 149 citationsPoints to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.Peter Nash, Andreas Kerschbaumer, Thomas Dörner, Maxime Dougados, Roy Fleischmann
Annals of the Rheumatic Diseases. 2021-01-01
Press Mentions
JAK Inhibitors Show No Excess Cardiovascular Safety Signal in French Nationwide CohortOctober 20th, 2022- JAK Inhibitors Show No Excess Cardiovascular Safety Signal in French Nationwide CohortOctober 19th, 2022
- Monoclonal Antibody, Antiviral Therapies Struggle to Keep Pace with COVID-19 VariantsFebruary 11th, 2022
- Join now to see all
Grant Support
- Mycobacterial Disease Prevention: Pharmacovigilance And Inflammatory DiseaseAgency For Healthcare Research And Quality2008–2010
